FDA Cybersecurity Deficiency Response for Imaging AI & SaMD
Resolve FDA cybersecurity deficiency letters fast for imaging AI and SaMD - model lineage, DICOM, cloud tenancy, and PCCP-aligned security responses.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
Cybersecurity deficiency letters for imaging AI and SaMD typically cluster around three themes: incomplete SBOM (especially missing OS-layer or model artifacts), insufficient threat modeling of the cloud architecture and tenancy boundaries, and missing security architecture views for the inference and writeback paths. We've closed deficiency letters in this segment that were structured exactly that way. Our 24-hour gap analysis maps each item in your AI letter or hold letter to the specific FDA guidance section it references - current 524B guidance, the AI/ML PCCP draft, and the 2026 final premarket guidance - and identifies whether the gap is a documentation problem, an analysis problem, or an actual product-side gap that needs a design change.
For imaging AI specifically, the most common 'real' (not just documentation) gaps we resolve are: tenant-isolation evidence missing for the cloud inference path, model-update path not security-modeled in the PCCP, DICOM security profiles not analyzed, and SBOM that doesn't include model weights or container OS layers. We rebuild the affected SPDF sections, add the missing threat model coverage, regenerate the SBOM with VEX, and produce a response letter structured for the reviewer who issued the deficiency - changes flagged, justifications cross-referenced to guidance sections, and the package eSTAR-ready. We stay engaged through any second round at no additional cost.
FDA Deficiency Response engagement, end to end
Four phases, fixed fee, scoped to imaging & ai/samd architecture from kickoff onward.
-
01
Scope + kickoff
Architecture review, attack-surface walkthrough, and threat-model alignment with your team. Written scope in 24 hours.
-
02
Threat-model alignment
Every STRIDE entry in your threat model is matched to a planned test case so reviewers see one-to-one coverage.
-
03
Test execution
Device, cloud, mobile, BLE/RF, and OTA channels exercised in parallel by senior engineers - not a single web-app scan.
-
04
Reviewer-ready report + retest
eSTAR-format report with findings, CVSS, remediation, and unlimited retests until every finding is closed.
What we see in Imaging & AI/SaMD fda deficiency response
The patterns we hit in this segment, this service, again and again.
-
SBOM rejected for missing OS-layer + model components
Common pattern: pip-freeze SBOM accepted at first submission, rejected with 'incomplete' on review. We rebuild as multi-layer CycloneDX with model artifacts.
-
Tenant isolation not demonstrated
Cloud architecture described, isolation controls not evidenced. Resolved by adding tenant-isolation control test evidence to the SPDF and threat model.
-
PCCP doesn't address model-update security
PCCP focuses on clinical performance bounds. Reviewer asks how a malicious model update is prevented - we add that branch to the PCCP cyber controls.
-
DICOM security profile choice not justified
Product uses no DICOM security profile. Response documents the threat-model rationale and compensating controls.
"Blue Goat Cyber takes the burden off our engineers and makes FDA cybersecurity requirements easy to understand. Their expertise and smooth process mean we can focus on our product, not the paperwork. The organized documentation, perfectly formatted for eSTAR, saves us countless hours."
Standard FDA Deficiency Response deliverables
The same deliverables the parent FDA Deficiency Response service ships with - tuned to your imaging & ai/samd architecture.
- 24-hour gap analysis: We map every item in the deficiency letter against the specific FDA guidance section it references - so the response addresses what reviewers actually want, not what the letter superficially says.
- Remediation package: Every artifact identified in the gap analysis is rebuilt or updated - SPDF sections, SBOM, test evidence, or threat model - formatted for the eSTAR template and traceable to the deficiency items.
- Reviewer-ready response: The final package is structured for the FDA reviewer who issued the letter - changes are flagged, justified, and cross-referenced so they can close the deficiency without a second round.
- Post-submission support: We stay on the engagement until the deficiency is resolved - if FDA responds with a second round, we address it at no additional cost.
What lands in your eSTAR submission
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
- 24-hour gap analysis: We map every item in the deficiency letter against the specific FDA guidance section it references - so the response addresses what reviewers actually want, not what the letter superficially says.
- Remediation package: Every artifact identified in the gap analysis is rebuilt or updated - SPDF sections, SBOM, test evidence, or threat model - formatted for the eSTAR template and traceable to the deficiency items.
- Reviewer-ready response: The final package is structured for the FDA reviewer who issued the letter - changes are flagged, justified, and cross-referenced so they can close the deficiency without a second round.
- Post-submission support: We stay on the engagement until the deficiency is resolved - if FDA responds with a second round, we address it at no additional cost.
Standards that apply
The Imaging & AI/SaMD baseline, plus the call-outs that matter for fda deficiency response in this segment.
Segment-specific call-outs
FDA 2026 final premarket guidance + AI/ML PCCP
Deficiency responses must cite the exact guidance section. We track the cross-reference to the guidance line, not just the document.
ANSI/AAMI SW96
Reviewer expectations for SaMD threat-model rigor are anchored here.
What's not in scope
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
- Hospital enterprise IT network penetration testing
- Clinical efficacy or human-factors validation
- Physical security of manufacturing sites
- Source-code review (unless explicitly added as a separate engagement)
FDA Deficiency Response for Imaging & AI/SaMD - FAQs
The questions buyers in this segment actually ask before scoping a fda deficiency response engagement.
Go deeper on Imaging & AI/SaMD and premarket
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
The most common cybersecurity deficiencies in 510(k), De Novo, and PMA submissions, what triggers each one and how to fix it before you file. Aligned to the FDA February 2026 final guidance and Section 524B.
When HIPAA applies to medical device manufacturers, how the 2025 Security Rule NPRM raises the bar, and how HIPAA obligations intersect with the FDA's Feb 2026 premarket cybersecurity guidance.
Which EHR and EMR systems medical devices connect to (Epic, Oracle Health, MEDITECH, Allscripts, athenahealth), the integration protocols (HL7, FHIR, DICOM), and the cybersecurity risks the FDA expects you to document.
How Health Canada regulates medical device cybersecurity in 2026: pre-market license expectations, MDEL obligations, and how to reuse an FDA Section 524B package.
Other engagements for Imaging & AI/SaMD
Teams in this segment commonly bundle these alongside fda deficiency response.
Keep going
Scope a FDA Deficiency Response engagement for your imaging & ai/samd program.
A 30-minute call with a senior engineer who has done this in imaging & ai/samd before - not a sales rep.